Alkermes
ALKS
#3093
Rank
S$6.31 B
Marketcap
S$38.25
Share price
0.75%
Change (1 day)
-8.37%
Change (1 year)

P/E ratio for Alkermes (ALKS)

P/E ratio as of December 2025 (TTM): 14.1

According to Alkermes's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.0942. At the end of 2024 the company had a P/E ratio of 12.9.

P/E ratio history for Alkermes from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202412.9-0.04%
202312.9-147.4%
2022-27.2-64.89%
2021-77.5172.37%
2020-28.575.82%
2019-16.2
2017-53.130.98%
2016-40.6-22.32%
2015-52.2-82.16%
2014-293

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Acorda Therapeutics
ACOR
-0.0676-100.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
17.6 25.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
19.4 37.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
15.1 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
29.7 111.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
44.9 218.72%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Zogenix
ZGNX
-6.56-146.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
13.3-5.49%๐Ÿ‡ซ๐Ÿ‡ท France
Novartis
NVS
18.1 28.18%๐Ÿ‡จ๐Ÿ‡ญ Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.